COL18A1 and non-small cell lung carcinoma: Ouyang Lihui et al. conducted a meta-analysis in 2012 to compare the efficacy of gemcitabine + cisplatin + recombinant human endostatin (GPE) regimen and gemcitabine + cisplatin (GP) regimen in patients with NSCLC; GPE is superior to GP in total effective rate and disease control rate.